A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.

Journal of Translational Medicine
Osama E RahmaSamir N Khleif

Abstract

Due to the lack of specific tumor antigens, the majority of tested cancer vaccines for renal cell carcinoma (RCC) are based on tumor cell lysate. The identification of the von Hippel-Lindau (VHL) gene mutations in RCC patients provided the potential for developing a novel targeted vaccine for RCC. In this pilot study, we tested the feasibility of vaccinating advanced RCC patients with the corresponding mutant VHL peptides. Six patients with advanced RCC and mutated VHL genes were vaccinated with the relevant VHL peptides. Patients were injected with the peptide mixed with Montanide subcutaneously (SQ) every 4 weeks until disease progression or until the utilization of all available peptide stock. Four out of five evaluable patients (80%) generated specific immune responses against the corresponding mutant VHL peptides. The vaccine was well tolerated. No grade III or IV toxicities occurred. The median overall survival (OS) and median progression-free survival (PFS) were 30.5 and 6.5 months, respectively. The vaccine demonstrated safety and proved efficacy in generating specific immune response to the mutant VHL peptide. Despite the fact that the preparation of these custom-made vaccines is time consuming, the utilization of VHL ...Continue Reading

References

Oct 1, 1977·The Journal of Urology·S Z FreedM Gordon
Jun 1, 1991·Research in Immunology·C J Melief, W M Kast
Sep 1, 1988·The Journal of Urology·A W RitchieJ B deKernion
Feb 15, 1995·JAMA : the Journal of the American Medical Association·W M LinehanB Zbar
Nov 1, 1994·The British Journal of Ophthalmology·G Langmann, K Müllner
May 1, 1994·Nature Genetics·J R GnarraF M Duh
Oct 9, 1996·International Journal of Cancer. Journal International Du Cancer·N BrouwenstijnP I Schrier
Oct 1, 1996·Seminars in Immunology·D MumbergH Schreiber
May 1, 1998·The New England Journal of Medicine·R C Young
Mar 27, 1999·Journal of Immunotherapy·S N KhleifJ Schlom
May 11, 1999·JAMA : the Journal of the American Medical Association·W H ChowJ F Fraumeni
Oct 5, 2001·Lancet·G H MickischUNKNOWN European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group
Jan 30, 2002·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael Thun
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James C YangSteven A Rosenberg
Feb 21, 2004·CA: a Cancer Journal for Clinicians·Ahmedin JemalUNKNOWN American Cancer Society
Oct 27, 2004·Expert Opinion on Biological Therapy·Johannes Vieweg, Andrew Jackson
Jun 25, 2005·Current Medicinal Chemistry·Eliada Lazoura, Vasso Apostolopoulos
Jun 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David P CarboneJay A Berzofsky
Jul 26, 2005·Cytotherapy·A DiabM-A Perales
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Robert J MotzerM Dror Michaelson
Sep 21, 2006·Journal of the National Cancer Institute·John M HollingsworthBrent K Hollenbeck
Oct 7, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C J A PuntU Keilholz
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·W Marston LinehanLen Neckers
Apr 5, 2007·Journal of the National Cancer Institute·Wong-Ho ChowSusan S Devesa
Jan 15, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Jon J Hiles, Jill M Kolesar
Feb 26, 2008·Cancer Immunology, Immunotherapy : CII·Antoun ToubajiSamir N Khleif
Mar 13, 2008·World Journal of Urology·Hirotsugu Uemura, Marco A De Velasco
Aug 13, 2008·Expert Opinion on Biological Therapy·Marij J P WeltersSjoerd H van der Burg
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Oct 10, 2013·Nature Biotechnology·Cedrik M BrittenUlrich Kalinke
Oct 15, 2014·British Journal of Cancer·V BoisguérinU Sahin
Sep 8, 2015·Vaccines·Cheryl Lai-Lai ChiangLana E Kandalaft
Dec 24, 2013·Advances in Chronic Kidney Disease·Naomi B Haas, Katherine L Nathanson
Mar 26, 2013·International Journal of Urology : Official Journal of the Japanese Urological Association·Kazuhiro Yoshimura, Hirotsugu Uemura
Jul 15, 2015·Oncoimmunology·Pierre CombeStéphane Oudard
Aug 1, 2020·Nature Communications·Kevin LitchfieldCharles Swanton
Mar 6, 2021·Human Vaccines & Immunotherapeutics·Yuexin XuScott S Tykodi
Oct 30, 2021·Cancer Cell·Lewis AuUNKNOWN TRACERx Renal Consortium

❮ Previous
Next ❯

Methods Mentioned

BETA
leukapheresis
surgical resection
dissection

Software Mentioned

BIMAS
FACS Diva
FlowJo

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.